Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blackstone Life Sciences (“BXLS”) today announced a $455 million collaboration with Boston Scientific Corporation (NYSE: BSX) to co-fund the development of the VITALYST™ Temporary Percutaneous Transvalvular Circulatory Support System program. The VITALYST system is a next-generation, miniature heart pump intended to increase cardiac output and improve blood flow from the heart to the brain and other vital organs. It is designed to treat acute myocardial infarc